- Home
- TLSA vs IKNA Comparison
TLSA vs IKNA Comparison
Compare TLSA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- IKNA
- Stock Information
- Founded
- TLSA 2013
- IKNA 2016
- Country
- TLSA United Kingdom
- IKNA United States
- Employees
- TLSA N/A
- IKNA N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- IKNA Health Care
- Exchange
- TLSA Nasdaq
- IKNA Nasdaq
- Market Cap
- TLSA 87.8M
- IKNA 83.0M
- IPO Year
- TLSA 2000
- IKNA 2021
- Fundamental
- Price
- TLSA $1.20
- IKNA $1.68
- Analyst Decision
- TLSA
- IKNA Buy
- Analyst Count
- TLSA 0
- IKNA 2
- Target Price
- TLSA N/A
- IKNA $3.00
- AVG Volume (30 Days)
- TLSA 145.8K
- IKNA 41.6K
- Earning Date
- TLSA 05-10-2024
- IKNA 11-07-2024
- Dividend Yield
- TLSA N/A
- IKNA N/A
- EPS Growth
- TLSA N/A
- IKNA N/A
- EPS
- TLSA N/A
- IKNA N/A
- Revenue
- TLSA N/A
- IKNA $1,844,000.00
- Revenue This Year
- TLSA N/A
- IKNA N/A
- Revenue Next Year
- TLSA N/A
- IKNA N/A
- P/E Ratio
- TLSA N/A
- IKNA N/A
- Revenue Growth
- TLSA N/A
- IKNA N/A
- 52 Week Low
- TLSA $0.41
- IKNA $1.02
- 52 Week High
- TLSA $1.74
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- IKNA 51.57
- Support Level
- TLSA $0.83
- IKNA $1.68
- Resistance Level
- TLSA $0.92
- IKNA $1.78
- Average True Range (ATR)
- TLSA 0.09
- IKNA 0.04
- MACD
- TLSA 0.03
- IKNA 0.00
- Stochastic Oscillator
- TLSA 84.52
- IKNA 36.36
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.